Grants8 logo Grants8
Login Create account

Grant Details

https://www.grants.gov/search-results-detail/344880

Grant Analysis

Purpose & Target

  • Core objective: To provide federal financial assistance for high-quality conferences and scientific meetings that research and investigate topics clearly aligned with the FDA mission and impact public health.
  • Explicit identification of target recipient type: Organizations capable of hosting scientific conferences/meetings.
  • Size: Not specified.
  • MUST state if grant is 'SECTOR-SPECIFIC' or 'SECTOR-AGNOSTIC': SECTOR-SPECIFIC
  • Geographic scope and any location requirements: Implied to be US-based organizations due to the funder being the U.S. Food and Drug Administration.
  • Key filtering criteria for initial grant screening: Relevance to the FDA's mission, type of meeting (symposium, seminar, workshop, formal meeting), and exclusion of clinical trials.
  • Grant frequency and program context: Recurring opportunity with annual application deadlines through October 2025, reissued from PAR-19-306.

Financial Structure

  • Funding type: Federal financial assistance.
  • Budget range: Not specified; no minimum or maximum grant amounts are stated.
  • Currency: USD.
  • Eligible and ineligible costs: Not detailed in the provided information.
  • Matching fund requirements: None specified.
  • Co-financing requirements: None specified.
  • Payment schedule and mechanisms: Not detailed, but an award will not be issued unless it can be issued before the conference start date.
  • Financial reporting requirements: Not detailed in this document.
  • Indirect cost policies: Not detailed.

Eligibility Requirements

Organizational Type & Status
  • Applicants must be organizations capable of hosting high-quality conferences and scientific meetings. Specific types like 'SME' or 'NGO' are not defined, implying a broader institutional eligibility.
  • Prior approval in the form of a Letter of Intent (LOI) is required before submission of an application.
  • The grant award must be issued before the conference start date.
Geographic Requirements
  • Organizations must be based in the United States (implied by funder, U.S. Food and Drug Administration).
Project Specifics
  • The conference or scientific meeting must be designed to research and investigate a topic clearly aligned with the FDA mission.
  • A conference/meeting is defined as a symposium, seminar, workshop, or any formal meeting, whether conducted face-to-face or virtually, to exchange information and explore a defined subject, issue, or area of concern impacting the public's health within the scope of the FDA's mission.
  • Projects involving clinical trials are not allowed ('Clinical Trial Not Allowed').
Formal Requirements
  • The Letter of Intent (LOI) must be submitted no later than 8 weeks prior to the selected application due date; LOIs received after this period will not be accepted.

Application Process

Key Dates and Deadlines
  • Latest Application Due Date: October 10, 2025, by 11:59 PM Eastern Time.
  • Letter of Intent (LOI) Due Date: 8 weeks prior to the selected application due date. LOIs received after this deadline will not be accepted.
  • Open Date (Earliest Submission Date): February 1 (for April due dates) and August 1 (for October due dates) in 2023, 2024, 2025.
Application Process
  • Prior approval (advance permission to apply) in the form of an LOI is required.
  • Required Application Instructions: Applicants must follow the Research (R) Instructions in the SF424 (R&R) Application Guide, except where specifically instructed otherwise in this Funding Opportunity Announcement (FOA) or related NIH Notices.
  • Submission Format and Platform: Applications must be submitted through Grants.gov using one of the following options: NIH ASSIST system, an institutional system-to-system (S2S) solution, or Grants.gov Workspace.
  • Application must be submitted error-free (of both Grants.gov and eRA Commons errors) by the due date. Late applications will not be accepted.
Review and Award Timeline
  • Scientific Merit Review: Generally occurs in June for April deadlines and December for October deadlines (approximately 2-3 months after application receipt).
  • Earliest Start Date: Generally July for April deadlines and January for October deadlines. Applicants are strongly encouraged to pursue funding at least 6 months in advance of the anticipated meeting date.
Post-Award Requirements
  • Reporting schedule and frequency: Not detailed in the provided information.

Evaluation Criteria

The provided text explicitly states that 'The FDA does not follow the NIH Page Limitation Guidelines or the NIH Review Criteria.' Instead, the FDA uses its own 'Objective Review Process'. Therefore, specific, detailed evaluation criteria are not provided in this document. Implicit Evaluation Factors (based on grant purpose):
  • Alignment with FDA Mission: The primary objective is to support conferences aligned with the FDA's mission and public health impact, which will undoubtedly be a key scoring factor.
  • Quality of Conference/Meeting: The grant aims to support 'high-quality' conferences and scientific meetings, suggesting that the proposed quality of the event, its agenda, speakers, and expected exchange of information will be assessed.
  • Relevance of Topic: The topic's relevance to specific FDA components (e.g., CBER, CDER, CDRH, CTP, CVM, CFSAN, NCTR, OC, ORA) and broad public health concerns will be important.

Compliance & Special Requirements

Regulatory Compliance
  • Applicants must conform to all requirements outlined in the SF424 (R&R) Application Guide and this specific Funding Opportunity Announcement (FOA).
  • Where this FOA provides specific written guidance that differs from general grant application form guidance, applicants must follow the instructions given in this FOA.
Specific Exclusions/Limitations
  • This grant mechanism (R13) is specifically for 'Clinical Trial Not Allowed' projects.
  • The FDA does not adhere to NIH Page Limitation Guidelines or NIH Review Criteria; applicants should consult FDA Agency Contacts for specifics regarding page limits and their objective review process.
Intellectual Property Policies
  • Not detailed in the provided information.
Risk Management and Security Requirements
  • Not detailed in the provided information.
Unique Aspects and Considerations
  • Permission to submit a conference grant application does not assure funding or funding at the level requested.
  • Participating FDA components include: Center for Biologics Evaluation and Research (CBER), Center for Drug Evaluation and Research (CDER), Center for Devices and Radiological Health (CDRH), Center for Tobacco Products (CTP), Center for Veterinary Medicine (CVM), Center for Food Safety and Applied Nutrition (CFSAN), National Center for Toxicological Research (NCTR), Office of the Commissioner (OC), and Office of Regulatory Affairs (ORA).

Grant Details

fda conference scientific meeting public health biologics drugs medical devices tobacco veterinary medicine food safety toxicology regulatory affairs research support grant united states r13
FDA Support for Conferences and Scientific Meetings (R13 Clinical Trial Not Allowed)
PAR-23-072
FDA Scientific Conference Grant Program
OTHER
US
HEALTHCARE OTHER
OTHER
OTHER
SDG3
FUNDING
1000000.00
None
None
USD
None
Oct. 11, 2025, 4:59 a.m.
June and December annually, following April and October deadlines.